Recommendation of the President – Quviviq (daridoreksant)
On 21 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 9/2026 on the reimbursement of the medicinal product Quviviq (daridoreksant) for the indication of non-organic insomnia in cases of ineffectiveness and/or intolerance of alternative drug technologies available on the Polish market